Future Cures

Robot Surgeries, Immunotherapies, Gene Therapies…with our increased capacities with technology, the world of cancer research and cures is exploding with possibilities. The next 10 years holds great promise.  But for those of us struggling in the moment, at the end of our ropes, the future cannot come soon enough. The problem is that Cancer is not one specific disease, but rather many intersecting and interlocking diseases.

Nonetheless Precision medicine, which targets exact mutations, along with immunotherapy holds great promise as does stem cell research.  Below are some of the most recent research findings.  Some are more readable than others, but for you science wonks, or for those of you like me who are willful to understand, here are some peer reviewed findings from the research on cancer cures.  They are categorized by subheadings: Gene Therapy, Immunotherapy, Stem Cell Research, Germ-line Therapy, etc..



Improving Outcomes in Resectable Gastric Cancer: A Review of Current and Future Strategies.

BA BPharm, RW Jang, RK Wong, CJ Swallow… – Oncology (Williston Park, …, 2016
Future Strategies. BPharm BA, Jang RW, Wong RK, Swallow CJ, Darling GE, Elimova
E. Gastric cancer is a highly fatal malignancy, and surgery alone often does not
provide a cure, even for relatively early stages of disease.


Twelfth Annual Meeting of the French Society of Cell and Gene Therapy

E Verhoeyen, S Gomez, A Galy, E Ayuso, P Midoux… – Human Gene Therapy, 2016
HUMAN GENE THERAPY, VOLUME 27 NUMBER 7 To provide a viable approach to treating infants,
Marc Kay’s group has developed an AAV promoterless gene-targeting approach without the use
of nucle- ases and used this tactic to successfully treat mice with

Cancer suicide gene therapy: a patent review

SA Navarro, E Carrillo, C Griñán-Lisón, A Martín… – Expert Opinion on …, 2016
Abstract Introduction: Cancer is considered the second leading cause of death worldwide
despite the progress made in early detection and advances in classical therapies.
Advancing in the fight against cancer requires the development of novel strategies, and

The Target’s the Thing

TR Flotte – 2016
The Target’s the Thing. To cite this article: Flotte Terence R.. Human Gene Therapy. In the
1970s, many conceived of the Nixon administration’s “War on Cancer” as the search for a single
breakthrough that would allow for effective treatment of all forms of cancer, as if cancer

Theranostic Imaging of Cancer Gene Therapy

TV Sekar, R Paulmurugan – Methods in molecular biology (Clifton, NJ), 2016
Abstract Gene-directed enzyme prodrug therapy (GDEPT) is a promising therapeutic
approach for treating cancers of various phenotypes. This strategy is independent of various
other chemotherapeutic drugs used for treating cancers where the drugs are mainly

… Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 …

D Niedzwiecki, WL Frankel, AP Venook, X Ye… – Journal of Clinical Oncology, 2016
21 Other than a marginal treatment effect in the Quick and Simple and Reliable (QUASAR analysis
of the stage II cohort in Intergroup 0035 suggested that fluorouracil therapy might be a direction
for future research would be to show that prognostic gene expression signatures

[HTML] The long noncoding RNA CASC9 regulates migration and invasion in esophageal cancer

Z Pan, W Mao, Y Bao, M Zhang, X Su, X Xu – Cancer Medicine, 2016
16.77/100,000, respectively [3]. Despite the recent advances in EC treatment, the prognosis it
essential for uncovering the underlying mechanisms of EC for therapy improvement cell
proliferation, differentiation, transcriptional, and post-transcriptional regulators of gene activity [

The present and future of genome editing in cancer research

X Li, R Wu, A Ventura – Human Genetics, 2016
disease-causing mutations in somatic cells has long been the holy grail of gene therapy, and
genome a mutation in the FAH gene in the liver has been used to treat a mouse associated virus
(AAV), was recently shown to significantly improve the efficiency of FAH gene repair in

Development of Optimized AAV Serotype Vectors for High-Efficiency Transduction at Further Reduced Doses

C Ling, B Li, W Ma, A Srivastava – Human Gene Therapy, Part B: Methods, 2016
or organs, we utilized an NSG mouse xenograft model, in which human liver tumors are grown
following subcutaneous injection of human liver cancer lines26. NSG mice bearing human liver
Human gene therapy for RPE65 isomerase Treatment of leber congenital


D Sah, P Tan, W Cavenee, F Furnari, MDMI Perez… – US Patent 20,160,194,645, 2016
provides a pharmaceutical composition for inhibiting the expression of a deltaEGFR gene in an
with a non-dsRNA therapeutic agent, such as an agent known to treat a cancer be administered
with, eg, a chemotherapeutic agent, such as temozolomide, or with radiation therapy.

Nanoparticle-Mediated Delivery of Suicide Genes in Cancer Therapy

R Vago, V Collico, S Zuppone, D Prosperi, M Colombo – Pharmacological Research, 2016
Conventional chemotherapeutics have been employed in cancer treatment for decades due
to their efficacy in killing the malignant cells, but the other side of th.


Immunobiology and immunotherapy in genitourinary malignancies

M Tsiatas, P Grivas – Annals of Translational Medicine, 2016
Abstract Immunotherapy has traditionally been a critical component of the cancer treatment
armamentarium in genitourinary (GU) cancers. It has an established role in the management
of carefully selected patients with metastatic renal cell carcinoma (RCC)[eg, high dose

[PDF] Mutated neo-antigens as targets for individualized cancer immunotherapy

M Vormehr – 2016
Summary Carcinogenesis is largely driven by somatic gene mutations. Accumulating
evidence suggests that a significant subset of mutations result in neo-epitopes recognized
by tumor-specific T cells and thus may constitute the Achilles’ heel of malignant cells. T

Vaccination Against Breast Cancer and its Role in Prevention

BJ Czerniecki, N Nocera, L Lowenfeld, L Showalter… – Trends in Breast Cancer …, 2016
1995;181:2109–17.PubMedCrossRef. 30. Milani A, et al. Active immunotherapy in HER2
overexpressing breast cancer: current status and future perspectives. Ann Oncol. Page DB, Naidoo
J, McArthur HL. Emerging immunotherapy strategies in breast cancer. Immunotherapy.

M2 polarization of murine peritoneal macrophages induces regulatory cytokine production and suppresses T‐cell proliferation

S Oishi, R Takano, S Tamura, S Tani, M Iwaizumi… – Immunology, 2016
Th2 cytokines but not regulatory cytokines. Several basic and clinical immunotherapy
studies have been performed with cancer (19–22). Immunotherapy studies advance not
only the field of cancer but also the field of inflammatory disease.

Efficient regeneration of Human Vα24+ invariant NKT cells and their anti‐tumor activity in vivo

D Yamada, T Iyoda, R Vizcardo, K Shimizu, Y Sato… – STEM CELLS, 2016
Invariant NKT cells • NK cells • induced pluripotent stem cells • Reprogramming • Immunotherapy
ABSTRACT This study thus provides a first proof of concept for the clinical application of human
iPS-Vα24+iNKT cells for cancer immunotherapy. STEM CELLS 2016; 00:000–000

Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas

S Paydas, EK Bagir, MA Deveci, G Gonlusen – Medical Oncology, 2016
doi:10.1007/s12032-016-0807-z. Abstract. Programmed death-1 (PD-1) and programmed
death-ligand 1 (PD-L1) are new targets in cancer immunotherapy in recent years. Keywords.
PD-1 PD-L1 Immunotherapy Sarcoma. This study has been submitted to ESMO 2016 meeting. ..


Innovation in Bladder Cancer Immunotherapy.

HB Grossman, DL Lamm, AM Kamat, S Keefe… – Journal of Immunotherapy, 2016
Abstract Bladder cancer is understudied despite its high prevalence and its remarkable
response to immunotherapy. Indeed, funding for studies to explore mechanisms of tumor
immunity and novel new therapeutics is disproportionately lower for bladder cancer in

Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting

G Mountzios, H Linardou, P Kosmidis – Annals of Translational Medicine, 2016
Abstract Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related
death worldwide. In recent years, through a better understanding of the interactions between
the immune system and tumor cells (TC), immunotherapy has emerged as a promising

Prospecting TCRs for immunotherapy

Z Fehervari – Nature Immunology, 2016
The elimination of tumors through vaccination or the adoptive transfer of tumor-specific T
cells is an attractive option but is technically challenging because of difficulties in raising
robust and appropriate immune responses. In Science, Schumacher and colleagues study

[HTML] Cancer immunotherapy trials: leading a paradigm shift in drug development

LA Emens, LH Butterfield, FS Hodi, FM Marincola… – Journal for ImmunoTherapy …, 2016
Background Cancer immunotherapy has a long history in the clinic. William Coley was an
orthopedic surgeon in the late 1800’s who noted marked tumor regression in a patient with
severe erysipelas. Based on this observation, he hypothesized that stimulating the

[HTML] Purity of transferred CD8+ T cells is crucial for safety and efficacy of combinatorial tumorimmunotherapy in the absence of SHP-1

HA Watson, G Dolton, J Ohme, K Ladell, M Vigar… – Immunology and Cell …, 2016
Abstract Adoptive transfer of tumor-specific cytotoxic T cells is a promising advance in
cancer therapy. Similarly, checkpoint inhibition has shown striking clinical results in some
patients. Here we combine adoptive cell transfer with ablation of the checkpoint protein

CIMT 2016: Mechanisms of efficacy in cancer immunotherapy-Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy

LM Kranz, M Birtel, L Hilscher, C Grunwitz… – Human Vaccines & …, 2016
Cancer immunotherapy at its golden age is now included as a standard of care treatment for
cancer. Its well-established preclinical era has been flourishing in the recent decade with
many patients benefiting from the therapeutic efficacy of cancer immunotherapy through

Melanoma immunotherapy dominates the field

P Diamantopoulos, H Gogas – Annals of Translational Medicine, 2016
Abstract The incidence of melanoma is increasing worldwide and despite early detection
and intervention, the number of patients dying from metastatic disease continues to rise. The
prognosis of advanced melanoma remains poor, with median survival between 6 and 9

Human γδ T cells: From a neglected lymphocyte population to cellular immunotherapy: A personal reflection of 30years of γδ T cell research

D Kabelitz – Clinical Immunology, 2016
Please note that Internet Explorer version 8.x will not be supported as of January
1, 2016. Please refer to this blog post for more information. Close. ScienceDirect.
Sign in Sign in using your ScienceDirect credentials. Username.

Cellular immunotherapy for malignant gliomas

Y Lin, H Okada – Expert Opinion on Biological Therapy, 2016
Abstract Introduction: Cancer immunotherapy has made much progress in recent years.
Clinical trials evaluating a variety of immunotherapeutic approaches are underway in
patients with malignant gliomas. Thanks to recent advancements in cell engineering

[HTML] A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy

C Alvarez-Fernández, L Escribà-Garcia, S Vidal… – Journal of Translational …, 2016
Background Immunotherapy based on the adoptive transfer of gene modified T cells is an
emerging approach for the induction of tumor-specific immune responses. Memory stem T
cells, due to their enhanced antitumor and self-renewal capacity, have become potential

[HTML] Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy

LGL Sand, D Berghuis, K Szuhai, PCW Hogendoorn – … Immunology, Immunotherapy, 2016
Abstract Ewing sarcoma is an aggressive neoplasm predominantly occurring in adolescents
and has a poor prognosis when metastasized. For patients with metastatic disease in
particular, immunotherapy has been proposed as possible beneficial additive therapy.

Comparing Small Molecule, Immunotherapy and Combination Therapies for Colon Cancer

M Alamzai, C Gonzales – 2016
Abstract This project evaluates tumor volume in Balb/C mice inoculated with CT-26 tumor
cells to understand the efficacy of small molecule and immunotherapy drugs used
individually in comparison to combination therapy solutions. We hope that using the small

Updates on Therapies for Metastatic RCC

RW Joseph, NM Tannir – Oncology Times, 2016
Recently Approved Immunotherapy. Renal cell carcinoma has long been considered
to be an “immunogenic” tumor due to its ability to evade tumor immune surveillance.
For the past Future Immunotherapy Strategies. Based on the

[PDF] Cell reactions and immune responses to photodynamic therapy in oncology

MKL Łysenko, H Gerber, R Nowak – Postepy Hig Med Dosw (online), 2016
It is belie- ved that the unique properties of PDT combined with adjuvant immunotherapy may
offer not only simple destruction of the primary tumor but also stimulation of the host immune
system to recognize, track down, and ultimately destroy tumor cells that have metastasized


Cancer stem cell and treatment of breast cancer

H Tebyanian, A Karami, J Amani – Journal of Applied Tissue Engineering, 2016
Nat Rev Cancer 2005; 5: 275-284. Hu Y and Fu L. Targeting cancer stem cells: a new therapy
to cure cancer patients. American Journal of Cancer Research 2012; 2: 340-356. Jones RJ, Matsui
WH, and Smith BD. Cancer Stem Cells: Are We Missing the Target? ..

Bruceantin inhibits multiple myeloma cancer stem cell proliferation

ME Issa, S Berndt, G Carpentier, JM Pezzuto… – Cancer Biology & Therapy, 2016
Abstract Multiple myeloma (MM) continues to claim the lives of a majority of patients. MM
cancer stem cells (CSCs) have been demonstrated to sustain tumor growth. Due to their
ability to self-renew and to express detoxifying enzymes and efflux transporters, MM-CSCs


D Raleigh, B Tomlin, B Del Buono, E Roddy, K Sear… – Neuro-Oncology, 2016
Adjuvant treatment regimen was not predictive for PFS or OS by log-rank CONCLUSIONS:
Outcomes with adjuvant high-dose chemotherapy and stem cell transplant are comparable to
adjuvant craniospinal chemoradiation in select pediatric embryonal brain tumor patients.


M Dougherty, M Guzman, T Geller, L Brefeld, V Shetty… – Neuro-Oncology, 2016

Comparable outcomes following two or three cycles of high-dose chemotherapy and autologousstem cell transplantation for patients with relapsed/refractory germ …

Z DeFilipp, CB Rosand, DA Goldstein, VA Master… – Bone Marrow …, 2016
A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stemcell rescue for | Article |
PubMed | ISI | CAS |; International Germ Cell Cancer Collaborative Group. cell consensus
classification: a prognostic factor-based staging system for metastatic germ cell cancers.

[HTML] … Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell

BA Jonas, C Johnson, D Gratzinger, R Majeti – PloS one, 2016
Clinical Oncology Career Development Award (K12 CA138464; http://www.cancer.gov/grants
with guidelines from the Mouse Models of Human Cancers Consortium (MMHCC therapy-related
AML samples were CD3-depleted using Robosep (Stem Cell Technologies, Vancouver

Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer

E González-Billalabeitia, JM Sepúlveda, P Maroto… – European Urology Focus, 2016
L/G = level/grade; EC = expert consensus; GCC = germ cell cancer; IPSGC = International dose
combination with high-dose combination chemotherapy and stem cell transplant in need to fulfill
several requirements, including availability of a multidisciplinary tumor board and a

[HTML] MicroRNA-183 suppresses cancer stem-like cell properties in EBV-associated nasopharyngeal carcinoma

CCM Cheung, SWM Lun, GTY Chung, C Chow, C Lo… – BMC Cancer, 2016
cell (CSC) subpopulation was proposed to play a critical role in local relapse and metastasis
in human cancers [4, 5 It has been suggested that repression of these stemness-inhibiting miRNAs
maintains the stem cell phenotype and is implicated in cancer progression [13

Plasticity of lung cancer stem-like cells is regulated by the transcription factor HOXA5 that is induced by oxidative stress.

H Saijo, Y Hirohashi, T Torigoe, R Horibe, A Takaya… – Oncotarget, 2016
that control the plasticity is essential to achieve CSC/CIC-targeting therapy. In this study, we
analyzed the plasticity of lung cancer cells and found that lung non-CSCs/CICs can dedifferentiate
into CSCs/CICs in accordance with the expression of stem cell transcription factor

uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.

MA Pavón, I Arroyo-Solera, MV Céspedes, I Casanova… – Oncotarget, 2016
(2)Infections and Cancer Unit, Cancer Epidemiology Research role of the plasminogen activator
system in head and neck squamous cell carcinoma (HNSCC), particularly linked to the induction
of epithelial-to-mesenchymal transition, the acquisition of stem cell properties and

… aortic arch banding and debanding in mice as a model of pressure overload hypertrophy182Late sodium current inhibitors for the treatment of inducible obstruction …

E Andre, E Yaniz-Galende, C Hamilton, GJ Dusting… – Cardiovascular Research, 2016
Poster session 1Cell growth, differentiation and stem cells-Heart72Understanding the
metabolism of cardiac progenitor cells: a first step towards controlling their proliferation and
differentiation? 73Expression of pw1/peg3 identifies a new cardiac adul…| Cardiovascular


The effect of salvage autologous stemcell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X …

G Cook, AJ Ashcroft, DA Cairns, CD Williams… – The Lancet Haematology, 2016
The primary funder of the trial was Cancer Research UK (A7264), with Subsequently, 110 patients
underwent peripheral blood stemcell remobilisation 18 and 174 patients were demographic and
disease characteristics were well balanced between the treatment groups (table 1


[HTML] Tumor prevention facilitates delayed transplant of stem cell‐derived motoneurons

P Magown, RM Brownstone, VF Rafuse – Annals of Clinical and Translational …, 2016
Tumor prevention. When considering translation of stem cell therapies, it is crucial to be able
to prevent cancer formation.[16, 42] Tumor formation has been seen following the transplantation
of a number of cell types, including various human pluripotent cell lines.[43-47


Mechanisms of Cancer-related Cardiomyopathy67Protection against chemotherapy cardiotoxicity by the human amniotic fluid stem cell secretome: a new tool for …

E Lazzarini, PR Carter, M De Boer, C Balbi, P Altieri… – Cardiovascular Research, 2016
67 Protection against chemotherapy cardiotoxicity by the human amniotic fluid stem cell secretome:
a Introduction: Advances in diagnosis and therapy have made cancer curable in a substantial
such as anthracyclines, may become the major health problem in cancer survivors.


… of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European …

J Styczynski, W van der Velden, CP Fox, D Engelhard… – Haematologica, 2016
Transplantation (EBMT-IDWP), the Infectious Diseases Group of the European Organization for
Research and Treatment of Cancer (EORTC-IDG), the To better define current understanding
of post-transplant lymphoproliferative disorders in stem cell transplant patients, and to


[HTML] Wnt Signaling in Cancer Stem Cell Biology

F de Sousa e Melo, L Vermeulen – Cancers, 2016
in Wnt signaling regulation relevant for CSC biology comes from hepatocellular carcinoma (HCC
targeting of the Wnt pathway is unlikely to show efficacy in cancers with genetic of a subset of
Wnt target genes that are particularly important for (cancer) stem cell proliferation [106


Contribution of INTRAMUSCULAR Autologous Adipose Tissue-Derived Stem Cell Injections toTreat Cutaneous Radiation Syndrome: Preliminary Results

D Riccobono, D Agay, S François, H Scherthan… – Health Physics, 2016
Abstract: Cutaneous radiation syndrome caused by high
dose located irradiation is characterized by d.


Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine

KJ Briggs, P Koivunen, S Cao, KM Backus… – Cell, 2016
Cancers with activating mTOR mutations accumulate high HIF1 levels due to increased HIF1A
transcription and MB-468; M157, MDA-MB-157; M231, MDA-MB-231; RCC, renal cell carcinoma.
To study this further, we made an Hs578T breast cancer subclone harboring a firefly


[PDF] YAP down-regulated its target CTGF to maintain stem cell pluripotency in human ovariancancer stem-like cells

X Wang, K Zhang, L Yang, S Wan, Y Liu – Int J Clin Exp Pathol, 2016
Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis. [12] Ricci
F, Bernasconi S, Perego P, Ganzinelli M, Russo G, Bono F, Mangioni C, Fruscio R, Signorelli M,
Broggini M, Damia G. Ovarian car- cinoma tumor-initiating cells have a


[PDF] Synergistic Chemo–Photothermal Therapy of Breast Cancer by Mesenchymal Stem Cells Encapsulated Yolk–Shell GNR@ HPMO-PTX Nanospheres

J Wu, Y Liu, Y Tang, S Wang, C Wang, Y Li, X Su… – ACS Applied Materials & …, 2016
3 photosensitizer-loaded silica nanoparticles to breast cancer cells for photodynamic
therapy.8 It is found that the therapeutic agents delivered by MSCs are homogeneously and
enduringly distributed in the tumor, which is favorable for improving treatment efficacy.6,9 However


The Role of Induction Therapy for Esophageal Cancer

MF Berry – Thoracic Surgery Clinics, 2016
8 This article reviews the evidence and guidelines related to the use of either chemotherapy or
radiation therapy before esophagectomy for esophageal cancer. Role of induction therapy.
Surgery is considered integral to achieving cure in patients with esophageal cancer.


Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer

E González-Billalabeitia, JM Sepúlveda, P Maroto… – European Urology Focus, 2016
Abstract. Background. High-dose chemotherapy (HDCT) has been studied in several
clinical scenarios in advanced germ cell cancer (GCC). Objective. To caution. HDCT
can cure a significant proportion of heavily treated GCC patients.

[HTML] Association of germline genetic variants in RFC, IL15 and VDR genes with minimal residual disease in pediatric B-cell precursor ALL

M Dawidowska, M Kosmalska, Ł Sędek… – Scientific Reports, 2016
Here we present the findings of the search for association between the MRD status and 23
germline variants, 20 localized in genes and 3 in intergenic regions. In a candidate gene approach,
the genes were selected based on their involvement in metabolic pathways


ES Revazova, LN Kuzmichev, NA Turovets, JD Janus – US Patent 20,160,186,133, 2016
of the oocyte donors, as seen in the parthenogenetically-derived monkey ES cell line Cyno-1
of the present invention can also be differentiated into derivatives of all three germ layers in
pluripotent cells and cell lines, preferably human pluripotent cells and cell lines, which are

The present and future of genome editing in cancer research

X Li, R Wu, A Ventura – Human Genetics, 2016
1). Initially tested in cell lines (Choi and Meyerson 2014), the feasibility of this strategy was first
it is important to consider that CRISPR-based somatic genome editing and conventional germ
line gene– targeting methods are The library is then transduced into the desired cell line.

Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome

B Gao, K Lindemann, L Anderson, S Fereday, J Hung… – Gynecologic Oncology, 2016
Primary peritoneal cancer has been reported not only in women with their ovaries in situ, but
also in women carrying a germline BRCA mutation after prophylactic oophorectomy [3]. In some
cases primary BRCA germline mutation, 0.500. Lines of systemic therapy, 0.247.

The role of precision medicine for the treatment of metastatic renal cell carcinoma.

C Ciccarese, V Di Nunno, R Montironi, M Fiorentino… – Expert Review of Precision …, 2016
4) Hereditary tumors carry specific germline and pathognomonic mutations, which could help
versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival
onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine

Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes

D Wang, C Li, Y Zhang, M Wang, N Jiang, L Xiang, T Li… – Gynecologic Oncology, 2016
In line with this, the current study with wild-type PIK3CA ovarian cancer cells and our to PARP
inhibition in one of the three wild-type PIK3CA ovarian cancer cell lines, e.g lethality by inhibiting
PARP in tumor cells harboring BRCA deficiency caused by germline mutation, somatic

[PDF] Analysis of PBase Binding Profile Indicates an Insertion Target Selection Mechanism Dependent on TTAA, But Not Transcriptional Activity

D Yang, R Liao, Y Zheng, L Sun, T Xu – International Journal of Biological Sciences, 2016
Use of the piggyBac transposon for germline transformation of insects. Nolan T, Bower TM, Brown
AE, Crisanti A, Catteruccia F. piggyBac-mediated germline transformation of the piggyBac
transposition into primordial germ cells is an efficient tool for transgenesis in chickens.

In vitro functional screening as a means to identify new plasticizers devoid of reproductive toxicity

A Boisvert, S Jones, L Issop, HC Erythropel… – Environmental Research, 2016
DINCH® were tested for their in vitro toxicity using Leydig and spermatogonial mouse testicular
cell lines. all, 22 compounds were analyzed for their toxicity levels on Leydig and germ cells
(Fig. 34 °C, 5% CO 2 . Despite its unknown metabolic competency, this cell line has been

Personalized treatment of prostate cancer: better knowledge of the patient, the disease and the medicine

F Aoun, EE Rassy, T Assi, J Kattan – 2016
to increase in patients with single nucleotide polymorphism of KLF6 a suppressor gene in prostate
with defects in other cancer-related genes and 8% with actionable pathogenic germline alterations
[3 in 49 patients with mCRPC who had received one to two prior lines of taxane.

Smart micelleplexes as a new therapeutic approach for RNA delivery

P Pereira, M Barreira, JA Queiroz, F Veiga, F Sousa… – Expert Opinion on Drug …, 2016
cellular processes such as cell viability, cell cycle regulation, differentiation, genetic Page 20.
guaranteeing the silencing, correction or introduction of specific genes with minimal application
in gene therapy owing to their unique beneficial features: a peculiar core-